363-23-5

Basic information

• Product Name: 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2
• Synonyms: 15-keto-13,14-dihydroprostaglandine2;9,15-DIOXO-11ALPHA-HYDROXY-PROST-5Z-EN-1-OIC ACID;13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2;(E)-7-[(1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid;13,14-Dihydro-15-keto-PGE2;13,14-Dihydro-15-ketoprostaglandinE2 solution;(5Z)-11α-Hydroxy-9,15-dioxoprosta-5-ene-1-oic acid;(5Z,11α)-11-Hydroxy-9,15-dioxoprost-5-en-1-oic acid
• CAS NO: 363-23-5
• Molecular Formula: C20H32O5
• Molecular Weight: 352.47
• Mol File: 363-23-5.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 538.1°Cat760mmHg
• Flash Point: 293.3°C
• Appearance: /
• Density: 1.086g/cm³
• Vapor Pressure: 7.98E-14mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: −20°C
• CAS DataBase Reference: 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2(CAS DataBase Reference)
• NIST Chemistry Reference: 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2(363-23-5)
• EPA Substance Registry System: 13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2(363-23-5)

Safety Data

• Hazard Codes: F,Xn,Xi
• Statements: 11-20/21/22-36/37/38-67-66-36
• Safety Statements: 16-26-36
• RIDADR: UN 1231 3/PG 2
• WGK Germany: 3
• Hazardous Substances Data: 363-23-5(Hazardous Substances Data)

Usage

Description

13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) is a metabolite of PGE2 and the primary PGE2 metabolite in plasma. It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase. Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).

Uses

13,14-Dihydro-15-ketoPGE2 is a primary metabolite of PGE2 in plasma.

Definition

ChEBI: The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.

InChI:InChI=1/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-17,19,23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,19-/m1/s1